NEW YORK – Zentalis Pharmaceuticals and Caris Life Sciences on Tuesday announced they have partnered on patient selection for Zentalis' targeted cancer drug trials, beginning with its Wee1 inhibitor ZN-c3 for advanced solid tumors.
For its part of the partnership, Caris will use its platforms to perform whole-exome and -transcriptome sequencing on patients, which Zentalis will use, together with real-world data, to help identify eligible patients for its clinical trials, including for ZN-c3.
Zentalis will retain ownership of its clinical candidates, which also include ZN-c5, a selective estrogen receptor degrader for ER-positive, HER2-negative breast cancer; ZN-d5, a BCL-2 inhibitor for hematologic malignancies; and ZN-e4, an EGFR inhibitor for non-small cell lung cancer.
"We believe Caris' unique and comprehensive profiling offerings combined with robust databases will enable us to optimize the development of our novel oncology therapeutics, as well as provide invaluable resources for patient recruitment," Zentalis CEO and Chairman Anthony Sun said in a statement.
Last year, New York-based Zentalis also inked a partnership with Tempus focused on using information gleaned from patient-derived organoids to inform its ZN-c3 development.